| Not Yet Recruiting | A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer NCT07332533 | Shanghai JMT-Bio Inc. | Phase 2 / Phase 3 |
| Not Yet Recruiting | JSKN003 Combined Treatment of HER2-positive Gastric Cancer NCT06998771 | Shanghai JMT-Bio Inc. | Phase 2 |
| Recruiting | A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First- NCT06764875 | AstraZeneca | Phase 3 |
| Recruiting | Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic NCT06846996 | Daiichi Sankyo | — |
| Recruiting | HER-2 B Cell Peptide Vaccine NCT06414733 | Pravin T.P Kaumaya | Phase 1 |
| Recruiting | A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastro NCT06532006 | Shanghai Henlius Biotech | Phase 3 |
| Recruiting | First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) NCT06730373 | Qilu Hospital of Shandong University | Phase 2 |
| Recruiting | Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens NCT06572319 | Zhejiang Cancer Hospital | Phase 1 / Phase 2 |
| Not Yet Recruiting | Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC NCT06439550 | The First Affiliated Hospital of Zhengzhou University | Phase 2 |
| Not Yet Recruiting | RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer NCT06492317 | The First Affiliated Hospital of Zhengzhou University | Phase 2 |
| Active Not Recruiting | ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer NCT06328738 | Enliven Therapeutics | Phase 1 |
| Recruiting | Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual NCT06253650 | Gruppo Oncologico del Nord-Ovest | Phase 2 |
| Recruiting | Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanc NCT07334431 | Henan Cancer Hospital | Phase 1 / Phase 2 |
| Unknown | 89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study NCT05955833 | Amsterdam UMC, location VUmc | Phase 1 |
| Unknown | Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC NCT05982834 | Fudan University | Phase 1 / Phase 2 |
| Recruiting | Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esop NCT05715931 | Yu jiren | Phase 2 |
| Active Not Recruiting | First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer NCT05586061 | Qilu Hospital of Shandong University | Phase 2 |
| Recruiting | A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 NCT05514717 | Mersana Therapeutics | Phase 1 |
| Unknown | [68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors NCT05619016 | Karolinska University Hospital | Phase 2 |
| Terminated | BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors NCT05555251 | BioInvent International AB | Phase 1 / Phase 2 |
| Unknown | RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer NCT05313906 | Henan Cancer Hospital | Phase 2 |
| Unknown | Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gas NCT05311189 | Shanghai Zhongshan Hospital | Phase 2 |
| Unknown | Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER NCT05270889 | Yonsei University | Phase 2 |
| Terminated | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Can NCT05091528 | Silverback Therapeutics | Phase 1 / Phase 2 |
| Unknown | Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System NCT05165602 | Peking University | — |
| Active Not Recruiting | Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and NCT05190445 | Pieris Pharmaceuticals, Inc. | Phase 2 |
| Unknown | Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer NCT05070598 | Shengjing Hospital | Phase 2 |
| Withdrawn | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With NCT04602117 | QuantumLeap Healthcare Collaborative | Phase 1 |
| Terminated | TAC T-cells for the Treatment of HER2-positive Solid Tumors NCT04727151 | Triumvira Immunologics, Inc. | Phase 1 / Phase 2 |
| Completed | Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophag NCT04920747 | Centre Hospitalier Universitaire de Besancon | — |
| Withdrawn | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advance NCT04464967 | NKGen Biotech, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors NCT04660929 | Carisma Therapeutics Inc | Phase 1 |
| Suspended | Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive So NCT04650451 | Bellicum Pharmaceuticals | Phase 1 |
| Completed | ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors NCT04319757 | Acepodia Biotech, Inc. | Phase 1 |
| Unknown | ctDNA Screening in Advanced HER2 Positive Gastric Cancer NCT04520295 | Ruijin Hospital | — |
| Completed | Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Can NCT04082364 | MacroGenics | Phase 2 / Phase 3 |
| Completed | PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors NCT03650348 | Pieris Pharmaceuticals, Inc. | Phase 1 |
| Completed | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Ge NCT03602079 | Klus Pharma Inc. | Phase 1 / Phase 2 |
| Completed | Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarci NCT03409848 | AIO-Studien-gGmbH | Phase 2 |
| Completed | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors NCT03319459 | Fate Therapeutics | Phase 1 |
| Completed | PRS-343 in HER2-Positive Solid Tumors NCT03330561 | Pieris Pharmaceuticals, Inc. | Phase 1 |
| Unknown | Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric Can NCT02378389 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |